title: A randomized study of cyclophosphamide and cis-platinum with or without doxorubicin in advanced ovarian carcinoma.
abstract: Two hundred sixty-seven patients with advanced epithelial ovarian carcinoma were randomized to cis-platinum and cyclophosphamide versus cis-platinum, cyclophosphamide, and doxorubicin. Complete pathological response, evaluated at second-look laparotomy and survival, showed no differences between the two treatment groups. Recurrence-free survival after negative second look was 61% at 24 months.
authors.affiliation: Danish Ovarian Cancer Group, Department of Oncology, University Hospital, Odense, Denmark.
authors.forename: K
authors.initials: K
authors.lastname: Bertelsen
authors.forename: A
authors.initials: A
authors.lastname: Jakobsen
authors.forename: J E
authors.initials: JE
authors.lastname: Andersen
authors.forename: S
authors.initials: S
authors.lastname: Ahrons
authors.forename: P H
authors.initials: PH
authors.lastname: Pedersen
authors.forename: H
authors.initials: H
authors.lastname: Kiaer
authors.forename: E
authors.initials: E
authors.lastname: Arffmann
authors.forename: P
authors.initials: P
authors.lastname: Bichel
authors.forename: E
authors.initials: E
authors.lastname: Boestofte
authors.forename: I
authors.initials: I
authors.lastname: Strøyer
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002277:Carcinoma / Q000188:drug therapy* / Q000401:mortality; D002945:Cisplatin / Q000008:administration & dosage; D002986:Clinical Trials as Topic; D003520:Cyclophosphamide / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D005260:Female; D006801:Humans; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000401:mortality; D011897:Random Allocation
chemical_list: D004317:Doxorubicin; D003520:Cyclophosphamide; D002945:Cisplatin